BRCA Mutation Risk Underestimated by BRCAPRO Model

Share this content:
BRCA Mutation Risk Underestimated by BRCAPRO Model
BRCA Mutation Risk Underestimated by BRCAPRO Model

(HealthDay News) — Use of the BRCAPRO model for assessment of the likelihood of having a germline BRCA1/BRCA2 mutation, based on age, ethnicity, and family history, may underestimate the risk of mutations, according to a study published online March 17 in the Journal of Clinical Oncology.

Molly S. Daniels, from the University of Texas MD Anderson Cancer Center in Houston, and colleagues calculated BRCAPRO scores for 589 patients with ovarian cancer referred for genetic counseling at three institutions. The BRCAPRO predictions were compared with observed mutations.

RELATED: New Study May Pave Way for Detecting Ovarian Cancer Earlier

The researchers found that 31% of patients with ovarian cancer tested positive for BRCA1 or BRCA2 mutation. More mutations were observed than expected with BRCAPRO scores <40% (93 mutations observed vs. 34.1 mutations expected; P < 0.001). Twenty-eight percent of mutations (51 of 180) would have been missed if patients with BRCAPRO scores <10% had not been tested.

The risk for high-grade serous ovarian cancers was underestimated with BRCAPRO, but it overestimated the risk for other histologies (P < 0.001). Underestimation increased with decreasing age at diagnosis, and there was institution-level variation in model performance (both P = 0.02).

RELATED: Gynecologic Cancers Resource Center

"This study demonstrates that assessment of family history by a validated model cannot effectively target testing to a high-risk ovarian cancer patient population, which strongly supports the recommendation to offer BRCA1/BRCA2 genetic testing to all patients with high-grade serous ovarian cancer regardless of family history," the researchers wrote.

Reference

  1. Daniels MS, Babb SA, King RH, et al. Underestimation of Risk of a BRCA1 or BRCA2 Mutation in Women With High-Grade Serous Ovarian Cancer by BRCAPRO: A Multi-Institution Study. J Clin Oncol. 2014; doi:10.1200/JCO.2013.50.6055.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs